Clinical trial with CO-1177: a preliminary report.
The therapeutical efficacy and the clinical and biological tolerance of a treatment with a new mucolytic agent, CO-1177 (Nesosteine), were assessed by evaluating clinical symptoms and functional respiratory parameters in 40 patients suffering from acute relapsing bronchitic syndrome. The therapy was performed for 15 days, at the dosage of one vial given intramuscularly twice daily for the first seven days and then of one tablet orally thrice daily for the remaining eight days. A marked mucolytic activity of the drug was clearly evident from the first days of treatment, with consequent loosening of secretions obstructing the bronchial tract, and prompt improvement both of clinical symptoms and of functional parameters in all the patients. In no case was clinical or biohumoral intolerance observed.